Assessing the role of ustekinumab dose escalation in Crohn’s disease patients with loss of response: an observational study
UST dose escalation, in the form of reinduction or increased frequency to every 4 weeks may be effective among patients with loss of response or partial response, though predictors of response and strategy of escalation remain unclear.
Authors
- Péter L. Lakatos (ORCID: https://orcid.org/0000-0002-3948-6488)
- Valérie Heron (ORCID: https://orcid.org/0000-0002-4289-7501)
- Waqqas Afif (ORCID: https://orcid.org/0000-0001-6869-0982)
- Talat Bessissow (ORCID: https://orcid.org/0000-0003-2610-1910)
- Alain Bitton (ORCID: https://orcid.org/0000-0001-7214-1978)
- Davide De Marco (ORCID: https://orcid.org/0000-0001-8711-6337)
- Gary Wild (ORCID: https://orcid.org/0000-0002-9625-3437)
Institutions
- Semmelweis University (HU)
- McGill University Health Centre (CA)
- Hôpital Maisonneuve-Rosemont (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Journal of the Canadian Association of Gastroenterology
- Published
- 2025-01-28
- DOI
- https://doi.org/10.1093/jcag/gwaf001
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00